Dosing of first patient is expected to happen this month by Margarida Maia, PhD | July 11, 2024 Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for...
“One of the common problems we see in our clinic is that often patients continue to get worse clinically, but there are no changes on their MRI. In other words, we don't know the reason why patients are getting worse, despite having no new lesions or relapses.”...
Link to original article: Foralumab eases fatigue in most SPMS patients in access program (multiplesclerosisnewstoday.com) Foralumab found to ease fatigue in SPMS patients in access program Use of nasal spray reduced levels after 6 months in 7 of 10 patients in EAP by...
Foralumab's anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients. Link to original article: Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active Secondary...
Link to original article: Neurology Today (lww.com) The fully human anti-CD3 antibody foralumab attenuates microglial activation in patients with non-active secondary progressive multiple sclerosis (na-SPMS) with progression independent of relapse (PIRA), according...
Significant Improvements in Progressive Multiple Sclerosis Through Foralumab Treatment Link to original article: Significant Improvements in Progressive Multiple Sclerosis Through Foralumab Treatment (neurologylive.com) Over a 6-month treatment period, investigators...
Six months of treatment with foralumab, administered into the nose, led to decreases in microglial activity in five of six people with nonactive secondary progressive multiple sclerosis (SPMS) involved in an expanded access program. Microglia are resident immune cells...
Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic of this neurodegenerative...
Sep. 12, 2023 By Mar de Miguel Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic...
FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease Aug 15, 2023 Isabella Ciccone, MPH Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active secondary progressive multiple sclerosis...
Through an expanded access program, new announced data from a small cohort of patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with foralumab (Tiziana Life Sciences), an investigational anti-CD3 monoclonal antibody, showed reduction...
Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (SPMS) who received treatment with Tiziana Life Science’s foralumab nasal spray. Microglia, resident immune cells in...
March 22, 2023 Nasally Administered Monoclonal Antibody for COVID-19 Emily Harris Article Information JAMA. Published online March 22, 2023. doi:10.1001/jama.2023.4000 Treating people with mild to moderate COVID-19 infections nasally with foralumab, an anti-CD3...
Nasal Foralumab Shows Promise in Regulating Inflammatory Response of COVID-19 Mar 15, 2023Ashley Gallagher, Associate Editor Study includes healthy individuals and those who had progressive multiple sclerosis with the nasally administered treatment. sdecoret /...
New T Cell Antibody Treatment Improves Outcomes For Covid Patients William A. Haseltine Contributor Mar 16, 2023,09:57am EDT The need for effective Covid-19 drugs is ever-expanding. Hundreds of millions, if not billions, have been infected by SARS-CoV-2 throughout the...
First Nasal Monoclonal Antibody Treatment for COVID-19 Shows Promise for Treating Virus, Other Diseases In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with COVID-19Similar reduction in...
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases In a pilot trial and clinical sample-based investigations, the drug Foralumab decreased inflammatory markers in patients with COVID-19 Date: March 8, 2023 Source:...
March 8, 2023 BWH’s investigators test Foralumab in pilot trial for Covid-19 Manufactured by Tiziana Life Sciences, Foralumab stimulates the immune system's regulatory T cells. The investigators found evidence that Foralumab dampened the inflammatory T cell response...